Renovia Inc., recently grabbed the headlines after its CEO, Marc Beer, pledged the company’s commitment to the development of various new products tailored to treat pelvic floor disorders. Such a commitment stems from Renovia’s $32 million funding coupled by a $10 million investment from venture debt.
Based in Boston, Renovia has developed a stellar reputation for developing exceptional therapeutic and diagnostic products to treat pelvic floor conditions such as urinary incontinence widely verified to affect over 250 million women worldwide. The company’s flagship project broke new grounds after receiving FDA endorsement in April.
The Longwood Fund is credited for playing an integral role in Renovia’s unprecedented success. Aside from donating substantial investment, the healthcare investment entity pulled all the stops to bring on board a synergetic partnership between the Missouri-based Ascension Ventures and New York-based Perceptive Advisors. The investment is precisely tailored to promote testing and the development of additional diagnostic and therapeutic products such as the eagerly awaited improved Leva device.
While addressing a press release, Renovia’s CEO, Marc Beer Renovia, hailed the renewed partnership from the prominent healthcare investment firm for supporting its vision to diagnose, cure and improve the health standards of affected women worldwide. By combining the innovative sensor technologies and a modern health platform, the company is in a unique position to provide customers with critical data related to various treatment options. More importantly, customers will be in a unique position to understand a multitude of pelvic floor disorders and their subsequent healthcare costs.
Marc Beer’s Background
Marc Beer is widely considered to be a seasoned and in-demand healthcare expert. With over two decades’ worth of experience in the commercialization and development of pharmaceuticals, devices, and biotechnology, he has consistently proven to be a force to reckon with in the healthcare industry. Marc Beer is credited for co-founding Renovia in partnership with Yolanda Lorie in 2016. The innovative and creative healthcare guru boasts an impressive resume that includes influential positions in companies such as ViaCell and Chairman of Good Start Genetics, Inc.
As ViaCell’s CEO, Marc Beer spearheaded the company’s preservation, development and collection of umbilical cord blood stem cells to lead the enterprise to remarkable success. Under his insightful leadership, ViaCell exponentially grew to become a public company staffed by over 300 employees. Alternatively, Marc also served as Genzyme’s Vice President of Global Marketing; a role specifically designed to promote commercial sales of various products focusing on rare disease populations. With such a stellar career, Marc Beer is undoubtedly an in-demand expert to any potential medical institution.